EP-1087: Screening for symptoms in HNC: Italian translation and validation of a patient-reported outcome  by Maddalo, M. et al.
S522                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
setting remains still controversial, despite the large 
consensus as a promising candidate to become a biomarker 
that could further improve application and efficacy of 
radiation therapy (RT) in head and neck squamous cell 
carcinoma (HNSCC). Moreover, most of the studies refer to 
series of patients who underwent RT alone or in combination 
with Cetuximab. We performed a retrospective analysis on 
the prognostic value of EGFR expression in HNSCC treated 
with surgery and postoperative RT.  
 
Material and Methods: We analyzed 69 patients with an 
histological diagnosis of HNSCC who underwent adjuvant RT 
after surgery in our Institute from 1997 to 2003. A 3D 
conformal RT was delivered with a 6MV accelerator using a 
conventional fractionation (median 60 Gy, range 34.2-70 Gy) 
Median follow-up was 3.73 years (range 0.17-12.25 ys). None 
of these patients were treated with postoperative 
concomitant chemotherapy. Tumor samples used for the 
determination of EGFR were obtained from surgical 
specimens. Membrane features (intensity, extension, 
distribution) and percentage of EGFR expression were 
evaluated and a statistical analysis (univariate) was 
conducted to correlate these parameters with Overall 
Survival (OS) and Disease Free survival (DFS).  
 
Results: EGFR was overexpressed in 45,5% of our patients 
(median value used as threshold). No significant correlation 
(p value= 0.90) has been found between patients with an 
overexpression of EGFR and OS or DFS. Among patients with 
laryngeal carcinoma, those with overexpressed EGFR have 
showed a lower OS (not statistically significant) and DFS 
(p=0.05). Considering separately the membrane features, the 
intensity of the EGFR staining has been found statistically 
correlated with both OS (p= 0.03) and DSF (p=0.001). 
Moreover, a stratification of patients was performed 
combining extension and intensity of EGFR immunolabelling 
in tumour cell membranes, and their distribution following a 
three-point score: patients with 3+ score (intense and 
complete labelling and patchy distribution) presented the 
lowest OS and DFS and the difference was highly significant 
for both OS and DFS (p= < 0.0001). The same result was 
observed in the subgroup of patients with a diagnosis of 
larynx carcinoma.  
 
Conclusion: Based on our results it is still reasonable that the 
analysis of EGFR expression, especially referring to 
membrane features, might be a prognostic value for OS and 
DFS in locally advanced HNSCC treated with adjuvant RT. A 
clinical validation in prospective trials of the suggested 
three-point score system could be useful to select patients 
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Purpose or Objective: Tumor hypoxia is a common feature of 
locally advanced head and neck cancer (HNSCC) that is 
associated with higher malignancy and increased 
radioresistance. Tumor-to-blood ratios ≥1.2 are generally 
thought to indicate hypoxia. Nevertheless, previous studies 
use various thresholds to define tumor hypoxia. The following 
analysis tries to elucidate which threshold may be the most 
appropriate to determine hypoxic volume in respect to 
treatment success. 
 
Material and Methods: A prospective study was performed to 
determine changes in tumor hypoxia during primary 
chemoradiation (pRCTx) of HNSCC at our institution. Tumor 
hypoxia was non-invasively assessed by [18F]-Fluoro-
Misonidazole (F-MISO) PET/CT 2.5 h p.i. at baseline (week 0) 
and in week 2 and 5 of treatment, respectively. Hypoxic 
volumes (HV) were generated using thresholding at different 
levels of 1.2, 1.3, 1.4, 1.5 multiplied with the background-
uptake, which was defined as SUVmean within the ipsilateral 
trapezium muscle, as advised by a nuclear-medicine 
specialist. ∆-values of decrease of HV (∆HV) during treatment 
were obtained in weeks 0, 2 and 5 and correlated with local 
failure. As four patients showed local failure (LF), two groups 
of four patients each were made: four showing LF, four 
patients showing complete remission (CR). Before t-test 
analysis normal sample distribution was confirmes with 
Shapiro–Wilk test. Significance-level was defined as p<0.005. 
 
Results: We analysed 4 patients without local failure in 
comparison to 4 patients with LF to show differences of ∆ -
values in weeks 0 to 2, 2 to 5 and 0 to 5 of the HV. All 
patients primarily treated for HNSCC with dRCTx were 
included. Each patient received a total dose of 70Gy in 35 
fractions. Concomitant cisplatin chemotherapy was 
administered in weeks 1, 4 and 7. The mean follow-up time 
was 16.9 months (range: 10-22 months). Mean time to LF was 
9.5 months (range: 6-15 months). For patients in CR all ∆ -HV 
(mean) show proportional decrease in weeks 0 to 5. This is 
true for every threshold factor from 1.2 to 1.5. In those 
patients showing LF, ∆ -HV (mean) demonstrates not only a 
decrease in HV but also some increase at each of the time 
increments. There is a general decrease (p=0.0073) between 
week 0 and 5, while between week 0 and 2 and 2 and 5, a 





Conclusion: A decrease in ∆ -HV (mean) was shown at any 
time point, for any factor the tumor-to-background-ratio was 
multiplied with, in patients with CR. In patients with LF, the 
hypoxic volume showed inconsistence over time, at least at 
one time of measurement there was an increase in hypoxic 
volume. The choice of the threshold for determination of 
hypoxic volume in FMISO-PET/CT remains a crucial question 
that could not be answered at this point. To elucidate this 
larger patient numbers are needed. 
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Purpose or Objective: The aim of this prospective 
observational study was to: (1) linguistically validate the 
Italian translation of the Vanderbilt Head and Neck Symptom 
Survey (VHNSS), a patient-reported outcome measure to 
screen for symptoms in the head and neck cancer (HNC) 
patients (pts) population; (2) perform a pilot test on the 
translated survey (VHNSS-IT) to assess the feasibility and 
utility, both for clinicians (cls) and for pts, of its 
administration in clinic as a symptoms’ screening procedure. 
 
Material and Methods: A multi-step linguistic process was 
conducted to generate and validate the VHNSS-IT: a forward 
translation, a backward translation and a patient testing (n = 
35). For the pilot test 6 cls and 38 pts were recruited. Each 
pts completed the survey before the scheduled visit with the 
cls. Time to completion (TC), caregiver help (CH) and VHNSS-
IT scores distribution reflecting symptom’s intensity (SI) were 
recorded. The visit of the first three pts of each cls was 
performed per standard of care and the cls had to review the 
VHNSS-IT after the visit; time of revision (TR), perception 
regarding the acceptability of time burden, ease of use, and 
identification of potential problems that were previously 
unrecognized were reported. For the last three pts, cls were 
allowed to review the questionnaire during the visit, 
reporting the global perceived utility (GU). 
 
Results: Two intermediate Italian versions were created 
during the process: the first Italian version derived from a 
reconciliation of three forward translations and the second 
Italian version derived from changes in the first version after 
the backward translation step. During the patient testing 
step only 2 pts reported problems with items comprehension 
and the rate of comprehension problems per single item was 
lower than expected: 2,9% in 16 items and 5,7% in 1 item. Pts 
could give suggestion in order to make items clearer and 
easier to understand: 43% of pts proposed a revision of the 
survey and most of these suggestions were retained. For the 
pilot test median TR was 2’15’. Time burden was perceived 
to be acceptable for all cls; they all also found the 
questionnaire easy to use. The rate of GU was 100%. 
Reviewing the survey, 4 of 6 cls identified symptoms 
unaddressed during the visit (swallowing problems, 
xerostomia, mucus, pain, speech and hearing problems). 30% 
of pts requested CH: these pts were significantly older (p < 
0.001). Median TC was 6’57’’. TC was related to age (p = 
0.02), educational level (p = 0.023) and employment status (p 
= 0.004). Time after the start of the radiotherapy course (< 6 
months vs > 6 months) and surgery (yes versus no) were 
considered as variables that could possibly influence average 
SI scores per subscale. Figure 1 shows relevant findings. 
 
 
Conclusion: The VHNSS-IT represents a suitable instrument to 
screen for symptoms in Italian HNC pts treated with surgery 
and radio-chemotherapy and it can help cls to identify 
symptoms that require referral, education or intervention. 
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Purpose or Objective: The impact of time from symptoms to 
treatment on survival of head and neck squamous cell 
carcinoma (HNSCC) patients has been investigated with 
conflicting results. This might be explained by the 
heterogeneity of studies with respect to stage and treatment 
modality. To reduce bias, this study focused on patients 
diagnosed with stage III-IV HNSCC managed with definitive 
chemo-radiotherapy to assess the effect of total interval and 
treatment delay on survival. 
 
Material and Methods: Asingle-centre retrospective cohort 
analysis on 185 patients with stage III-IVHNSCC of oropharynx 
(n = 124), larynx (n = 36), and hypopharynx (n = 25)managed 
with definitive chemo-radiotherapy between 2008-2014 was 
performed. Patientscharacteristics included sex, age, smoke, 
Adult Comorbidity Evaluation (ACE-27),stage, tumor site, and 
HPV status (table 1). Treatment modalities 
includedconcomitant chemoradiation (CCRT, n = 33) for stage 
III patients, and inductionchemotherapy followed by 
radiotherapy (IC-CRT, n = 152) for stage IV patients.Total 
interval (time from first symptoms to the start of treatment) 
andtreatment interval (interval between the date of the 
pathology report and thestart of treatment) were defined in 
accord with the Aarhus StatementGuidelines. We chose 
